China has experienced rapid economic growth over the last ten years. Thanks to economic reforms in 1978, the country has experienced an explosion in productivity, capital investment and in the upskilling of its workforce[1]. Per capita GDP for each Chinese citizen has nearly tripled since 2008, according to a recent report[2], while college admissions have …
Read more A bright future ahead for cell line development in China
Solentim is excited to be attending and exhibiting at Oxford Global’s 8th Annual Cell Culture & Bioprocessing Congress, taking place 29-30 October in London. GSK, a valued customer of Solentim, will also be attending the event, and will be speaking on our VIPS technology. Gabriela Kozejova, Senior Scientist at GSK Stevenage, will present on Day …
Solentim, a global leader in cell line development instrumentation, is pleased to announce it will be attending and exhibiting at Biotech Week Boston, taking place 9-12 September. Camille Evenou, Scientist in cell line development at Celonic AG (Basel, CH), a customer of Solentim, will be talking in the Cell Line Development Pre-Conference Symposiumat 12pm on …
Read this new Bioprocessing Tutorial in the latest edition of Genetic Engineering News (GEN). In this educational piece, scientists at Solentim demonstrate the ways in which they have systematically been able to increase viability, recovery and outgrowth of single cells following single cell isolation in the cell line development process. As part of this, the …
NEWS – Bournemouth, UK – 8th August 2019: Solentim, the innovator and World leader in Cell Line Development instrumentation, is pleased to announce that it achieved very strong revenue growth and financial results for the first half of 2019. Commenting on the performance, Dr Ian Taylor, Chief Commercial Officer noted “Our results are in line with …
“Protein pharmaceuticals represent a multibillion-dollar market, but deciphering the most suitable biotherapeutic-producing cell lines is a substantial manufacturing bottleneck”, writes Lauren Tanabe for a recent article published by BioCompare. CHO cells have been the expression system of choice for producing biological therapies for several decades; they are accepted by the FDA, easy to work with, …
Read more Solentim in the Press: “Fast-Tracking Cell-Line Development”, BioCompare
